BMRN vs CL · P/E 40, rev $2.85B vs P/E 34, rev $20.38B
Biomarin Pharmaceutical Inc (BMRN) versus Colgate-Palmolive Company (CL) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Not investment advice. Open the BMRN and CL stock pages for the full models.
Not investment advice.